

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau**B2**

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 15/38, 5/16, 7/00, A01K 67/027</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 97/20935</b> <b>(43) International Publication Date:</b> 12 June 1997 (12.06.97)
<b>(21) International Application Number:</b> PCT/GB96/03033 <b>(22) International Filing Date:</b> 6 December 1996 (06.12.96) <b>(30) Priority Data:</b> 9524973.6 6 December 1995 (06.12.95) GB <b>(71) Applicant (for all designated States except US):</b> CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED [GB/GB]; The Old Schools, Cambridge CB2 1TS (GB). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> EFSTATHIOU, Stacey [GB/GB]; 18, Norwich Street, Cambridge CB2 1NF (GB). LACHMANN, Robin, Henry [GB/GB]; 45 Rathmore Road, Cambridge CB1 4AB (GB). <b>(74) Agents:</b> WALTON, Seán, M. et al.; Mewburn Ellis, York House, 23 Kingsway, London WC2B 6HP (GB).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> VIRAL VECTORS  <b>(57) Abstract</b>  Constructs for delivery of sequences of interest to cells include a herpes virus <i>latency active promoter</i> (LAP) of the <i>latency associated transcript</i> (LAT) region. An internal ribosome entry site (IRES) is located downstream of the LAP, with a nucleotide sequence of interest downstream of the IRES. Stable, long-term expression, including export of mRNA to the cytoplasm and translation of the encoded polypeptide, is found in neuronal and non-neuronal cells.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

## VIRAL VECTORS

The present invention relates to constructs for delivery of sequences of interest to cells of an individual, for instance using recombinant viruses.

5 This can have a therapeutic aim: and examples of the constructs and cells containing them can be useful also, for example, in production of a polypeptide which can then be used as desired (e.g. as an immunogen). By employing a *latency active promoter* of a *latency*  
10 *associated transcript* (LAT) region of a herpes simplex virus, long-term, high-level expression of a reporter sequence can be achieved.

It is often desirable to deliver exogenous DNA to  
15 cells in order to provide a missing gene or to help correct abnormal cellular behaviour. The present invention is not generally concerned with any difficulties that may be associated with delivery of nucleic acid to cells.

20 Many viruses have evolved to deliver nucleic acid into the nucleus of the cell, where it can be expressed. Certain viruses have been genetically engineered to carry a gene to be delivered, and can deliver it to host cells such as those the virus  
25 normally infects. Gene delivery vectors have also been based on attenuated or genetically disabled virus.

A number of genetically engineered viruses have been used to deliver foreign genes to cells both in vitro and in vivo. For certain purposes it is desirable for the gene to be stably expressed, producing biologically active amounts of its product on a long term basis. This remains a problem in a number of contexts.

Herpes Simplex Virus (HSV) is a ubiquitous pathogen of man which is capable of acutely infecting many cell types, and can persist long term in the sensory neurons of the host's dorsal root ganglia. This state, described as viral latency, is characterised by the persistence of the viral genome in the nucleus of the neuron without any detectable production of viral proteins, or interference with normal cellular metabolism. HSV's ability to establish latency in neurons makes it an attractive candidate as a gene delivery vector for the nervous system.

Though the virus does not produce any detectable protein product during latency, there is continuing RNA transcription. This latency associated transcription comes from a single region of the viral genome (the *latency associated transcript* or LAT region) and is driven by the *latency active promoter* (LAP). The TATA box and basal transcriptional regulatory sequences,

which constitute the core LAT promoter, reside approximately 700bp upstream of the 2kb major LAT.

HSV-1 is considered a good candidate vector for  
5 CNS gene therapy because it is able to establish life-long latent infections in human sensory neurons. During latency, the viral genome appears to be maintained episomally, and hence there appears to be no danger of insertional mutagenesis or inactivation of  
10 host genes. Furthermore, there is no detectable production of viral proteins during latency, and no evidence that the latent state interferes with the normal metabolism of the host cell.

Viral gene expression during latency appears to be  
15 limited to 2 or 3 nuclear RNA species which accumulate to high levels in sensory neurons harbouring latent virus (the LATs) (3). These transcripts are driven by a complex promoter region (LAP) (4). A functional-LAT region is not essential for the establishment of  
20 latency, and viruses whose LAT region has been deleted can still establish latency (5), and in some cases, express LATs (6). In fact it seems that the LATs may be involved in reactivation, as LAT negative viruses do not reactivate efficiently (7). Latency can be  
25 established in the absence of any viral gene expression, and seems to be a default pathway for the

virus which enters a cell where productive infection is

Several different promoters to drive expression of a reporter gene (usually  $\beta$ -galactosidase) in animal models, have shown transient reporter gene expression, but that this is not long-lived. This has led to much work trying to define what elements of the LAT region and promoter (LAP) are involved in maintaining its long-term transcriptional activity.

Further work has been done to try to utilise the LAP and other sequence elements in the LAT region to facilitate long-term expression of reporter genes.

A rabbit  $\beta$ -globin gene inserted downstream of the TATA box of the LAP made  $\beta$ -globin RNA during latent infection, but at lower levels than LAT in wild type infection (8). When the experiments were repeated using the endogenous LAT promoters to drive  $\beta$ -galactosidase or nerve growth factor genes, no RNA could be detected by in situ hybridisation (9).

The same group have since used a recombinant defective virus with a Moloney Murine Leukaemia Virus (MMLV) LTR, Lac Z construct inserted into ICP4, and a deletion of the 5' part of LAT, and demonstrated  $\beta$ -galactosidase expression in sensory ganglia (10). Gene expression was also assessed in motor neurons of the hypoglossal nucleus, where there was abundant transient

expression. The results were taken to indicate that the MMLV LTR did not remain active during latency in motor neurons. When the MMLV LTR is moved away from the viral repeats (where it is near to endogenous LAT sequences) and inserted into the gC locus, it was not longer able to produce long-term gene expression. If the region upstream of the LAP is also inserted into the gC locus upstream of the LTR, this virus is capable of producing gene expression in sensory neurons. The LAT sequences did not have similar facilitating effects when inserted upstream of the murine metallothionein promoter (11).

Other groups have also used the LAT promoter in vectors. Wolfe et al used a recombinant virus with the  $\beta$ -glucuronidase (GUSB) gene inserted into a LAT deletion downstream of the LAP in an attempt to correct the deficiency in GUSB deficient mice (12). A corneal infection route was used, and, although there was no phenotypic improvement in the condition of the mice, they were able to detect some GUSB positive cells as much as 18 weeks post inoculation. Miyahara et al have used a variety of HSV-1 vectors to attempt to deliver genes to the liver of mice (13). Using a LAT promoter to drive HbsAg or canine factor IX, they saw low levels of protein in the serum for about 3 weeks after direct injection of the vector into the liver.

These studies suggest that the LAT promoter may be able to produce prolonged, albeit low level, expression of foreign genes in the CNS and even in non-neuronal cells.

5           Goins et al. *J. Virol.* 68: 2239-2252 (1994) and WO96/27672 postulated the presence of a second latency-active promoter, tested for by experiments involving transient gene expression, located in the HSV1 U<sub>L</sub> flanking repeats.

10           Specification WO 96/27672 (published later than the priority date claimed for the present application) (Glorioso & Fink) concerns the structure of a herpesvirus promoter for transcription of a non-herpes gene in a cell latently infected with a herpes virus,  
15           e.g. peripheral neurons and cranial nerve ganglia.

          HSV-1 based vectors have also been constructed using lytic cycle HSV promoters (gC (14), IE110 (15)), strong non-specific promoters (CMV IE MMLV LTR) and neuron specific promoters (NSE (16)). On the whole,  
20           these studies show only transient gene expression in both peripheral and CNS neurons. As discussed above, the MMLV LTR can give long-term expression, but only when inserted close to LAT elements.

          The present inventors now show experimentally that  
25           by inserting a reporter gene, preceded by an internal ribosomal entry site (to allow efficient translation),



downstream of the LAP in the LAT region, a vector that gives stable, high level reporter gene expression during viral latency can be produced.

5           In initial attempts to construct HSV vectors which would give long-term gene expression the present inventors decided to use a murine RNA polymerase I (RNA pol I) promoter reporter gene construct inserted into the LAT region. RNA pol I is responsible for the  
10 transcription of ribosomal RNAs, and is active in all cell types. Native RNA pol I transcripts are not capped, and are not recognised by the translational apparatus of the cell, but, by inserting an internal ribosomal entry site (IRES) sequence immediately  
15 upstream of the reporter gene, it is possible to get efficient translation from such a transcript (17). By inserting this construct into the LAT region of HSV, which is known to be transcriptionally active during latency, the present inventors hoped to show RNA pol I  
20 activity during latent infection.

          The experimental work is described in detail below. Unexpected results were obtained. No activity of the RNA pol I was detected during latency when a reporter construct was inserted into a HpaI deletion in  
25 the LAT region in the opposite orientation to the direction of LAT transcription. However, anti-sense

transcripts of the reporter gene sequence were detected in the cytoplasm, showing that the LAT region had been modified for LAP activity to drive during latency expression of transcripts which were exported to the cytoplasm. (Lachmann, Brown and Efstathiou (1996), *J. Gen. Virol.* 77: 2575-2582). An enzyme reporter gene construct inserted into the same site for expression in the correct orientation gave efficient, long-term expression of enzyme activity.

10

According to a first aspect of the present invention there is provided a nucleic acid construct comprising (i) a portion of the latency associated transcript (LAT) region of a herpes simplex virus (HSV) genome, which portion comprises a latency active promoter (LAP), (ii) an internal ribosomal entry site (IRES) and (iii) a nucleotide sequence heterologous to the herpes virus LAT region.

The heterologous nucleotide sequence may be said to be "operably linked" to the LAP and the IRES for expression of the sequence of amino acids. The term "operably linked" with respect to a nucleotide sequence (such as a coding sequence) and a promoter means that the nucleotide sequence is positioned or disposed in the nucleic acid construct relative to the promoter suitably for transcription of the nucleotide sequence

25

to be under the control of the promoter. With respect to a nucleotide sequence and an IRES, the term "operably linked" means that the nucleotide sequence is positioned or disposed in the nucleic acid construct relative to the IRES suitably for the IRES to perform its function, i.e. for translation of an mRNA transcript of the sequence to be stimulated or enhanced (i.e. compared with an equivalent construct lacking an IRES operably linked to the nucleotide sequence).

10 Elements of the LAT promoter important for long term gene expression are not disrupted by insertion of foreign DNA sequences downstream of the LAT transcription site. Transcription of heterologous sequences in constructs according to the present invention may initiate from the LAT transcription start site, the transcribed RNA being exported to the cytoplasm of latently infected cells.

An IRES is an RNA sequence which facilitates ribosomal attachment and translation from an ATG methionine codon internal to an mRNA. Examples known per se include sequences encoded by picornaviruses. These have been divided into 3 groups; IRES sequences from entero and rhino viruses, from cardio and apthoviruses and from hepatitis A virus. IRES sequences have also been described in other viruses such as hepatitis C and recently in some non-viral

organisms.

Mutants, variants and derivatives of naturally occurring IRES sequences may be employed in the present invention provided they retain the ability to enhance  
5 translation.

The portion of the LAT comprising a LAP may be subject to mutation or alteration or one or more nucleotides, e.g. by insertion, addition, deletion or substitution to provide a mutant, variant or derivative  
10 of a naturally-occurring sequence. Those skilled in the art realise that it is possible to make changes to a nucleic acid molecule which either have no effect on its function or will modulate the level of the activity of interest. Changes which do have an effect may  
15 modulate the level of activity in a manner which is useful, e.g. to increase the level of expression or any other desirable property. The present invention must be taken to extend to constructs comprising a mutant, variant or derivative of a LAT sequence, as long as  
20 expression is viable in a suitable host cell.

Many known techniques and protocols for manipulation of nucleic acid, for example in preparation of nucleic acid constructs, mutagenesis, sequencing, introduction of DNA into cells and gene  
25 expression, and analysis of proteins, are described in detail in *Molecular Cloning: a Laboratory Manual*: 2nd

edition, Sambrook et al., 1989, Cold Spring Harbor Laboratory Press and in *Current Protocols in Molecular Biology*, Second Edition, Ausubel et al. eds., John Wiley & Sons, 1992. The disclosures of Sambrook et al. and Ausubel et al. are incorporated herein by reference (as are all references mentioned herein).

The IRES is generally placed downstream of the LAP, while the heterologous nucleotide sequence is placed downstream of the IRES. The heterologous nucleotide sequence and IRES may be placed about 1.5kb downstream of the transcription start site of the LAT promoter.

The present inventors have found that such a construct may be used to provide efficient, high-level and long-term expression especially where the IRES and coding sequence are inserted downstream of the LAP in place of a HpaI restriction fragment of the LAT region. HpaI cuts after nucleotide 120,301 and before nucleotide 120,469 of the HSV-1 genome. The HSV-1 genome sequence is given in Perry and McGeoch (1988) J. Gen. Virol. 69:2831-2846. Attention is directed to the sequence information provided by Perry and McGeoch, incorporated herein by reference. The boundaries of the LAT promoter are predicted to lie between coordinates 117,010-120,301. They may lie between 118,439-120,301.

thus, according to a further aspect of the present invention there is provided a nucleic acid construct comprising (i) a portion of the *latency associated transcript* (LAT) region of a herpes simplex virus (HSV) genome, which portion comprises a *latency active promoter* (LAP), and (ii) a heterologous nucleotide sequence inserted in the region of a HpaI restriction fragment of the LAT region downstream of the LAP. The heterologous sequence may be inserted in place of the HpaI restriction fragment, or in an adjacent or nearby site. Those skilled in the art can readily determine, by experiments guided by the present disclosure and involving otherwise per se well known procedures, the variation which is possible from the specific insertion described herein without abolishing long-term gene expression.

Where the HSV genomic region employed is derived from HSV-2 rather than HSV-1, the heterologous nucleotide sequence may be inserted at around the same distance from the LAP transcription start site or in the equivalent genomic location in the HSV-2 sequence. The promoter regions of HSV-1 and HSV-2 are very similar. Even though there is some divergence in the sequence of the region in HSV-2 which is equivalent to the HpaI insertion site, the person skilled in the art can readily determine, by experimentation guided by the

present disclosure and involving otherwise per se well known procedures, the equivalent position in relation to the LAP of HSV-2 for insertion of a heterologous sequence to give long-term gene expression as disclosed.

The term "heterologous" is used to refer to a nucleotide sequence which is not normally or naturally found in the specified position within the LAT region. It may therefore be any sequence of nucleotides different from the sequence of the fragment found naturally between the two HpaI restriction sites in the LAT region of the herpes simplex virus, i.e. the HpaI restriction fragment. As used in relation to a herpes virus "heterologous" may be used to refer to a non-herpes viral sequence, or a sequence not of the specific herpes virus in question. Possible alternative terminology includes "foreign" or "exogenous".

A heterologous nucleotide sequence may encode a sequence of amino acids, i.e. a peptide or a polypeptide.

Such a nucleotide sequence may be included in constructs of the present invention downstream of an IRES and/or in the region of the HpaI restriction fragment, as discussed. Advantageously, the sequence of amino acids is a protein such as a biologically

functional protein whose expression from the construct in cells of an individual has a therapeutic effect.

Alternatively, the nucleotide sequence may on transcription produce a RNA molecule which is able to influence expression of another gene by antisense regulation. The use of anti-sense genes or partial gene sequences to down-regulate gene expression is now well-established. Double-stranded DNA is placed under the control of a promoter in a "reverse orientation" such that transcription of the "anti-sense" strand of the DNA yields RNA which is complementary to normal mRNA transcribed from the "sense" strand of the target gene. The complementary anti-sense RNA sequence is thought then to bind with mRNA to form a duplex, inhibiting translation of the endogenous mRNA from the target gene into protein. Whether or not this is the actual mode of action is still uncertain. However, it is established fact that the technique works.

Another possibility is that the nucleotide sequence on transcription produces a ribozyme, able to cut nucleic acid at a specific site - and thus also useful in influencing gene expression. Background references for ribozymes include Kashani-Sabet and Scanlon, 1995, *Cancer Gene Therapy*, 2(3): 213-223, and Mercola and Cohen, 1995, *Cancer Gene Therapy*, 2(1), 47-59.



In addition to the said heterologous nucleotide sequence, such as a coding sequence, the heterologous nucleotide sequence may comprise one or more regulatory elements to enhance or improve transcription, and/or  
5 (for a coding sequence) translation.

In a further aspect, the present invention provides a nucleic acid construct including (a) a herpes viral LAT promoter, (b) located downstream of the promoter, a heterologous nucleotide sequence  
10 (polynucleotide), and (c) a further heterologous nucleotide sequence encoding a polyA tail, located downstream of the nucleotide sequence (b). As discussed, a heterologous nucleotide sequence located downstream of the promoter for transcription in the  
15 nucleus of a cell containing the construct may encode any desired product, including a polypeptide, an antisense RNA and/or a ribozyme.

In preferred embodiments of various aspects of the present invention the heterologous nucleotide sequence  
20 comprises an internal ribosome entry site (IRES) to enhance translation of the coding sequence.

Where a polynucleotide for transcription in a cell nucleus carrying a construct according to the present invention encodes an antisense or ribozyme sequence,  
25 there is no need to provide a ribosomal entry site.

Constructs according to the present invention may

be used for long-term expression. For instance, expression may be for at least about 26 days, preferably at least about 82 days, more preferably at least about 140 days, at least about 190 days, at least about 257 days, or at least about 307 days. We have observed long-term neuronal gene expression at 257 days post-infection in the peripheral nervous system and up to 9-10 months post infection in the central nervous system, including in the hypoglossal nucleus, facial nerve nucleus and cervical spinal cord. (See Table 1 and discussion in the experimental section below.)

Elements of the LAT promoter important for long term gene expression are not disrupted by insertion of foreign DNA sequences downstream of the LAT transcription site. Transcription of heterologous sequences in constructs according to the present invention may initiate from the LAT transcription start site, the transcribed RNA being exported to the cytoplasm of latently infected cells.

Embodiments of the invention include the use of viruses such as for example replication defective viruses to obtain long-term gene expression in latently infected cells.

In this connection, the constructs may form part of a vector for introduction into cells. The vector may be a plasmid. A viral vector may be used such as

an HSV vector or an HSV-derived vector, e.g. a mutant which is unable to initiate the cycle of productive infection and which may therefore be driven into the latent state or a mutant able to establish latency in cell-types other than neurons. Replication defective and/or attenuated viruses may be preferred for certain purposes.

A replication defective herpes virus may lack a functional form of one or more of the regulatory proteins ICP0, ICP4, ICP22, ICP27 and ICP47, and may lacking additionally or alternatively the essential glycoprotein H (gH) gene, or a functional form thereof. Propagation of a replication defective virus requires a complementing cell line. Cell lines able to complement both ICP4 and ICP27 gene defects have been constructed by Samaniego *et al.* (*J. Virol.* (1995) 69: 5705-5715). CRI cells are able to supply gH *in trans*.

A construct according to the present invention may for example be included in a replication defective virus which contains a deletion of the gH gene, and optionally also the ICP4 and ICP27 genes, which virus may be propagated in a suitable complementing host cell.

Thus, according to a further aspect of the invention there is provided a virus or a viral particle comprising as part of its genetic make-up or genome a

construct as disclosed. This may be used to introduce the construct into a cell, e.g. a cell of an individual.

5           Cells comprising a construct according to the present invention are provided as a further aspect of the invention, especially cells in which the construct is incorporated. Such cells may be in culture *in vitro*, and useful for study of expression etc., or may  
10       form part of a mammal, especially a non-human mammal such as a primate or rodent such as a mouse.

          Transgenic animals comprising cells which comprise a construct as disclosed also represent an aspect of the present invention, especially non-human mammals  
15       which may be used experimentally to investigate properties of the construct and/or therapeutic potential of delivery of any particular nucleotide sequence to cells of the body, such as neurons.

20           Methods which comprise introduction of a construct according to the present invention into a cell, e.g. by means of viral infection, are also provided by the invention. This may be performed *ex vivo* (*in vitro*) or *in vivo*. A method according to the present invention  
25       may include causing or allowing expression of a heterologous nucleotide sequence in a nucleic acid

19

construct, for instance within a cell following introduction of the construct into the cell or an ancestor thereof. A cell containing a construct according to the invention, e.g. as a result of  
5 introduction of the construct into the cell or an ancestor thereof, may be administered to a subject. Following such introduction, cells may be cultured or maintained *ex vivo* and then delivered to a subject, either from which they were obtained (or from which an  
10 ancestor was obtained) or a different subject. Where cells are to be used as an immunogen (for instance), they may be killed or inactivated prior to administration.

15 Also provided is a method comprising administration of a composition comprising a construct as disclosed to an individual. The administration may be by infection with a viral vector which comprises the construct. Naked DNA delivery may be used.

20 Stereotactic injection of the therapeutic virus into the nervous system as described by During *et al.* (ref. 2) is an accepted, efficient and widely used procedure for introducing substances to, or biopsying from, specific regions of the CNS in both humans and  
25 animals.

A further method according to an aspect of the

present invention includes administration of a herpes virus containing a construct as disclosed.

Administration is preferably in a "therapeutically effective amount", this being sufficient to show benefit to a patient. Such benefit may be at least amelioration of at least one symptom. The actual amount administered, and rate and time-course of administration, will depend on the nature and severity of what is being treated. Prescription of treatment, eg decisions or dosage etc, is within the responsibility of general practitioners and other medical doctors.

A composition may be administered alone or in combination with other treatments, either simultaneously or sequentially dependent upon the condition to be treated.

Pharmaceutical compositions according to the present invention, and for use in accordance with the present invention, may comprise, in addition to active ingredient, a pharmaceutically acceptable excipient, carrier, buffer, stabiliser or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient. The precise nature of the carrier or other material will depend on the

route of administration, which may be oral, or by injection, e.g. cutaneous, subcutaneous or intravenous.

For intravascular, cutaneous, subcutaneous, intramuscular, intraocular or intracranial injection, or direct injection into cerebrospinal fluid, injection into the biliary tree, or injection at the site of affliction, the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability. Those of relevant skill in the art are well able to prepare suitable solutions using, for example, isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection, Lactated Ringer's Injection. Preservatives, stabilisers, buffers, antioxidants and/or other additives may be included, as required.

The invention further provides a construct as disclosed, or a vector such as a virus comprising such a construct, for use in a method of treatment of the human or animal body, and use of such a construct or such a vector in the manufacture of a medicament or composition for use in treatment of the human or animal body. Treatment may be by administration as disclosed above.

Nucleic acid constructs and cells containing them are not just useful in a therapeutic context. It is

generally useful to be able to express nucleic acid stably within a host cell *in vitro*. The results reported herein indicate that stable, long-term expression can be achieved using constructs of the invention. This may therefore be employed in the production of a product encoded by a nucleotide sequence of interest, heterologous to the LAT region of a herpes virus, which may if need be recovered from a host cell for subsequent use. Polypeptides, for instance, are useful in raising antibodies in animals which may be used in the generation of hybridomas for monoclonal antibody production, and selection of antibodies or other binding molecules on columns or by means of bacteriophage display. A polypeptide produced by expression from a heterologous nucleotide sequence included in a construct according to the present invention may of course have a multitude of other uses, depending on the nature of the polypeptide itself.

A cell according to the present invention may be used as an immunogen, for instance, after a period of culture or maintenance *ex vivo* to allow expression of the heterologous polynucleotide, and optionally after treatment to kill or inactivate the cell.

Numerous other practical applications for constructs, vectors and cells according to the present invention are suggested by the experimental results.



## Nervous System Applications

### *Different Vector Systems*

HSV establishes a natural latent state in sensory  
5 ganglia neurons that can last the life time of the  
individual. There is also experimental evidence that  
defective HSV mutants, which have had certain of the  
genes required for a productive acute infection  
deleted, can also establish latency in CNS neurons.  
10 Such a vector containing a construct according to the  
invention should result in long-term expression of  
these cells as well.

The amplicon vector system consists of a plasmid  
containing the HSV origin of replication and packaging  
15 signals, as well as a promoter reporter gene construct,  
which can be packaged in a herpes virion for delivery  
(1). Such vectors produce good reporter gene  
expression in cells in tissue culture. When used to  
try to target genes to neurons in animal experiments,  
20 however, there has been less success. It has proved  
very difficult to find promoter constructs that will  
allow high level gene expression for long periods after  
infection. Insertion of a construct according to the  
present invention into an amplicon vector, maintains  
25 the LAT region sequences which give rise to long-term  
gene expression in the native viral genome and should

therefore produce long-term, high level expression of an inserted gene.

Similarly, the construct may be inserted into other viral vector systems (i.e. adenovirus, adeno-  
5 associated virus or retrovirus systems), or into plasmids used in non-viral delivery systems (e.g. liposomes) to achieve long-term reporter gene expression in the nervous system.

#### 10 *Metabolic Diseases*

There are many potential gene therapy applications within the nervous system. One of the main aims is to be able to complement various inborn errors of metabolism which affect the CNS by delivery of a copy  
15 of the missing gene. For many such conditions (e.g. Gaucher's Disease) it has been shown that the metabolic defects can be corrected by providing pharmacological amounts of the missing protein. Providing large quantities of such enzymes for pharmacotherapy is often  
20 not possible, and, where it is possible, extremely expensive. However, delivery using the present invention of the missing gene directly to the nervous system cells with long-term expression of physiological levels of protein, provides for correction of the  
25 metabolic defect with a single treatment. Thus, the present invention may be used for treating a large

25

number of such inherited conditions such as neuronopathic Gaucher's disease and other lysosomal storage disorders, metachromatic leucodystrophy,  $G_{M2}$  gangliosidosis, Huntingdon's disease and so on.

5           There are other neurological diseases due to acquired metabolic abnormalities. In Parkinson's disease there is a loss of cells in the substantia nigra which leads to a deficiency of the neurotransmitter dopamine in the caudate nucleus.

10          Patients can show a good therapeutic response to dopaminergic drugs, but if given orally large doses are needed and the side effects often limit treatment. In this condition it has been shown that providing a local source of the missing chemical in the basal ganglia of  
15          the brain can lead to dramatic resolution of symptoms. By delivering the tyrosine hydroxylase gene (which codes the enzyme that makes dopamine) to the cells of the basal ganglia, it is possible to obtain symptomatic relief in experimental models of the disease (2).

20          Again the present invention provides a way of obtaining long-term gene expression which may be useful for any of these applications. The approach may be usable for a number of other degenerative diseases of the nervous system, such as some of the dementias.

25

*Neoplastic Diseases*

Gene therapy has many applications in the treatment of cancer. There are a few rare cancers and neoplastic syndromes that are due to inherited genetic defects (i.e. retinoblastoma, multiple endocrine neoplasia, neurofibromatosis). Some of these may be treated or even prevented by supplying the missing gene by gene therapy. A number of these diseases can affect the cells of the nervous system. Again vector constructs according to the invention may be useful in treatments.

All cancer involves the accumulation of a number of acquired genetic abnormalities which combine to lead to uncontrolled cell division and growth. As we learn more about neoplasia, it is becoming clear that there are a small number of genes which are very important in the aetiology of a large number of cancers. Tumour suppressor genes, such as p53, are good examples of genes which have become inactivated in many neoplastic cell types. Gene therapy may be used to introduce a functional copy of the mutated gene into the neoplastic cells, and hence to arrest their growth. Vectors as disclosed herein may be useful for such applications within the nervous system.

Another approach to gene therapy for cancer is to deliver a suicide gene specifically to the malignant

cells which would produce a product which could, directly or indirectly, lead to their death. An example of such a strategy is to use the HSV thymidine kinase (TK) gene containing vectors to specifically transduce malignant cells. The patient is then given acyclovir, which is only metabolised to its active, toxic, metabolite in cells which contain the HSV TK gene. With specific delivery of such a suicide gene to neoplastic cells, constructs of the invention may be used to produce gene expression in neural derived tissue.

#### Application Outside the Nervous System

Although the LAP is probably most active in neurons, experiments in tissue culture have shown that it can be active in a wide range of other cell types. HSV can infect almost all cell types, though the only known site of natural latency is in neurons. As noted above, however, it is possible to make defective viruses which are not able to initiate the cycle of productive infection, and such a virus may be driven into the latent state in other cell types.

Then, the LAT region may still be transcriptionally active, though possibly at lower levels than in neurons. The advantage of using an IRES

(as discussed) is that it allows very efficient  
transcription of RNA, and to get appreciable levels of  
protein production from a low abundance transcript.  
This holds for amplification vectors as well as defective  
5 HSV vectors. Thus, HSV vectors containing a gene  
construct according to the invention may be used for  
gene delivery to any of a wide range of cell types,  
e.g. for tackling metabolic and neoplastic diseases, as  
described above.

10

Further aspects and embodiments of the present  
invention will be apparent to those skilled in the art,  
especially on consideration of the following  
experimental exemplification which is provided by way  
15 of illustration not limitation and with reference to  
the accompanying figures, wherein:

Figure 1 shows the plasmid pMENA which contains  
the murine RNA polymerase 1 promoter, an EMCV IRES and  
the neomycin resistance gene (ref. 17).

20 Figure 2 shows a map of the LAT region encoded by  
HSV-1. A series of restriction fragments cloned into  
pbluescribe (Stratagene) are shown. These plasmids are  
designated pSLAT1-pSLAT7. Introduction of foreign DNA  
sequences into the HSV genome was undertaken by  
25 deleting the HpaI fragment (nucleotide position  
120,301-120,469 relative to the HSV-1 genomic sequence)

of pSLAT1. End repaired foreign DNA was inserted into this locus. Linearized recombinant pSLAT1 was co-transfected with viral DNA and recombinant virus selected from the transfection progeny.

5           Figure 3 shows a map to show the structure of viruses C3b, C3b<sup>+</sup>, C3bneo and C3b $\Delta$ neo.

To make C3b and C3b<sup>+</sup> a cassette of the CMV IE1 promoter driving  $\beta$ -galactosidase was blunt-end cloned into the HpaI deletion in pSLAT1 (see Figure 1).

10          Clones containing the insert in each orientation were selected. The recombinant viruses were made by co-transfection of vero cells with PvuI linearised plasmid and HSV strain SC16 DNA. Transfection progeny was screened for  $\beta$ -galactosidase containing viruses, which  
15          were plaque purified.

A similar strategy was used to make viruses C3bneo and C3b $\Delta$ neo. The inserts were prepared from pMENA and p $\Delta$ MENA (Figure 2) as XhoI NotI fragments. These were cloned into the HpaI deletion of pSLAT1. Recombinant  
20          viruses were made by co-transfecting vero cells with linearised plasmid and C3b viral DNA. Recombinants no longer containing  $\beta$ -galactosidase were plaque purified.

Figure 4 shows plasmid pCA1.

This plasmid is based on the retroviral vector  
25          pBABE (ref: Nucleic Acids Research, 1990, 18, 3587).  
Into this a cassette containing the

encephalomyocarditis virus IRES driving a  $\beta$ -galactosidase neomycin phosphotransferase fusion gene ( $\beta$ -geo) has been cloned. The IRES is derived from the plasmid pEMC2 (Ann Kaminski, Department of  
5 Biochemistry, Cambridge).

Figure 5 shows a map to show the structure of viruses L $\beta$ A and L $\beta$ B.

These viruses were constructed using the IRES- $\beta$ -geo insert excised from pCA1 (Figure 4) as an XbaI  
10 fragment. This was cloned into the HpaI deletion of pSLAT1 (Figure 1). Recombinant virus L $\beta$ A was made by co-transfection of linearised plasmid with C3b<sup>+</sup> viral DNA (Figure 3). The recombinants express limited  $\beta$ -galactosidase activity in acute infections *in vitro*,  
15 and virus was purified by selecting plaques that did not stain blue with the X-gal reagent. Southern blot analysis of the structure of this virus shows that recombinant occurred within the  $\beta$ -galactosidase gene, and that no neoR sequences were present.

20 L $\beta$ B was made by co-transfection with C3b viral DNA (Figure 3) and recombinant virus purified as above. This virus contains the complete IRES $\beta$ geo sequence.

Figure 6 shows  $\beta$ -galactosidase expression in PNS from L $\beta$ A (Figure 6a) and L $\beta$ B (Figure 6b) infected mice.  
25 At each time point (days 4, 26, 82, and 190 for L $\beta$ A and days 5, 32 and 140) for L $\beta$ B) cervical DRG CII-CIV were



dissected from 5 to 6 mice and pooled for histochemical detection of  $\beta$ -galactosidase activity. After staining for 3 hours, the reaction was stopped, and the ganglia clarified in glycerol prior to microscopic examination and enumeration of the number of  $\beta$ -galactosidase expressing neurones.

All documents cited herein are incorporated by reference.

10

#### EXAMPLE 1

##### *Vectors Containing RNA Polymerase I Constructs*

A series of plasmids containing RNA pol I promoters driving expression of the neomycin resistance gene, with an encephalomyocarditis virus IRES inserted immediately 5' to the reporter gene (the pMENA series of plasmids) were obtained from Brian McStay (ref. 17) (Figure 1). The MENA construct was excised as a Xho I Not I fragment, end repaired and gel purified. This insert was then blunt end cloned into the small Hpa I deletion in pSLAT 1 (Figure 2), a plasmid designed to allow homologous recombination into the LAT region of HSV-1. Ampicillin resistant colonies were picked, and restriction enzyme analysis confirmed that clones containing the MENA insert in both orientations had

25

been obtained.

In order to avoid confusion with LAP activity, it was decided to insert the MENA construct so that RNA pol I transcription would be in the opposite direction to LAT transcription (Figure 3). The pSLAT1 clone  
5 containing the MENA insert in the correct orientation was prepared by CsCl ultracentrifugation, and linearised by digestion with Pvu I.

Viral DNA was prepared from Vero cells infected at  
10 multiplicity of 1 pfu/cell with C3b, and HSV-1 based virus containing the Lac Z gene inserted into the LAT locus (Figure 3). Cotransfections of Vero cells were done using a  $\text{CaCl}_2$  precipitation/DMSO shock protocol, and progeny virus was harvested after 3 days, when  
15 plaques were beginning to form. Plaque purification was performed under an agarose overlay containing the X-gal substrate, which gives a blue precipitate where  $\beta$ -galactosidase is present, and white plaques were picked. After 3 rounds of plaque purification, viral  
20 DNA was prepared, and Southern blot analysis performed to confirm viral structure.

This virus, containing the MENA construct inserted into the LAT region in the anti-sense direction to LAT transcription, is called C3bNeo. A further, similar  
25 virus was made using the same method to insert the  $\Delta$ MENA construct (containing a mutated, inactive RNA pol

I promoter) into the LAT region, C3bΔNeo (Figure 3).

RNA pol I activity from these viruses was initially assessed during acute infection of cells in tissue culture. Monolayers of BHK, Vero and 3T3 cells were infected at high multiplicity, and lysates prepared at various time points for assay of neomycin phosphotransferase activity. The results showed that there is specific RNA pol I activity, most actively in BHK cells, and that the IRES is able to allow efficient translation and production of protein product.

To investigate whether the C3bNeo virus exhibited any RNA pol I activity during latency, 6 week old female Balb/C mice were infected with  $2 \times 10^6$  plaque forming units (pfu) of C3bNeo by subcutaneous injection into the left ear (20  $\mu$ l injection volumes were used). Groups of 10 mice were sacrificed on day 30 and day 180 post infection. Left cervical dorsal root ganglia 2 through 4 were dissected from each mouse, pooled and fixed in periodate lysine paraformaldehyde (PLP) fixative for 1 hour. They were then transferred to 50% ethanol prior to mounting in wax.

5 micron sections were cut and *in situ* hybridisation performed using digoxigenin labelled riboprobes for both sense and anti-sense (as a control) Neor transcription. No neomycin phosphotransferase mRNA was detected, indicating that there was no

detectable transcription from the RNA pol I promoter in viral latency. Surprisingly, however, we were able to detect transcripts which were being made in the anti-sense direction to the MENA insert. These transcripts  
5 were localised to the cytoplasm and occurred at a frequency of 0.8 positive neurons per ganglionic section examined.

It seemed most likely that these transcripts represented LAP activity, and that, by making a large  
10 insertion into the LAT region, we had altered LAT processing such that the transcripts were no longer retained in the nucleus, but were exported to the cytoplasm. We confirmed that these cytoplasmic transcripts did contain LAT sequences by further ISH  
15 using probes for the 2 kb LAT.

We have also demonstrated cytoplasmic LAT transcripts in latency with the viruses C3b and C3b<sup>+</sup> (Figure 3). This shows that this phenomenon is not specific to the MENA insert, but appears to happen  
20 whatever insert is placed into this small Hpa I deletion.

The nuclear LATs seen in wild type HSV latency are unlikely to represent mRNA, as no translation can take place in the nucleus. It has been suggested that they  
25 might represent a stable intron which has been excised from a larger mRNA, but conclusive evidence for such a

large mRNA has not been found. Our insertion into the LAT region seems to have led to the production of a LAT species which is distributed like a mRNA.

In effect, this is a virus where the LAP drives  
5 expression of an mRNA species which can be detected at high levels during latency. From this, on insertion of a reporter gene into this locus or other adjacent loci within major LAT, observation of long-term gene  
10 expression was expected. However, there are a number of stop codons between the TATA box of the LAP and the Hpa I deletion used for insertion of coding sequences, and it seemed unlikely that a reporter gene inserted  
directly into this locus would be expressed.

## 15 EXAMPLE 2

### *Vectors Containing IRES-Reporter gene Constructs in the LAT Region*

A plasmid containing an encephalomyocarditis virus  
20 IRES linked to a Lac Z/Neo R fusion gene (termed  $\beta$ -Geo) (pCa1, fig 4) was obtained from Clare Abram (Dept of Pathology, Cambridge). The IRES- $\beta$ -geo insert was cut out as an Xba I fragment, and blunt end cloned into the Hpa I deletion of pSLAT 1. A clone containing the  
25 insert in the right orientation, sense to LAT (pSLAT 1  $\beta$ -Geo), was isolated, and DNA prepared by CsCl

ultracentrifugation.

Two viruses have been made using this insertion plasmid. The first was made by co-transfection with viral DNA from C3b<sup>+</sup> (Figure 3). The recombinant was plaque purified and its sequence analysed by Southern blot hybridisation. This showed that a the crossover had occurred during recombination within the *Lac Z* gene, and that the virus did not contain any *Neo R* sequences. This virus is called L $\beta$ A (Figure 5).

A second virus was made by cotransfection of Vero cells with pSLAT 1  $\beta$ -Geo and C3b DNA. Again the recombinant virus was plaque purified and its structure confirmed by Southern blot. This virus is called L $\beta$ B (Figure 5).

Both these viruses have a shared phenotype in acute infections of Vero cells in tissue culture. If a suspension plaque assay is performed, and staining for  $\beta$ -galactosidase performed, the plaques are predominantly white, but, if examined under the microscope, each plate will contain a few strongly positive blue cells, giving a unique speckled effect. Hence it seems that during acute infection of these non-neuronal cells, the LAP can be active, but only in a proportion of the cells. What constitutes the switch for LAP activity is unclear.

LAP is supposed to show a degree of neuronal

specificity, so LAP activity from these viruses was studied during acute and latent infections of mice.

11 female Balb/C mice, aged 5-6 weeks, were infected with  $5 \times 10^6$  pfu of L $\beta$ A in their left ears, and 5 mice with  $5 \times 10^6$  pfu C3b. 5 mice from each group were sacrificed at day 5 post infection, and the remaining L $\beta$ A mice were sacrificed at 26 days post infection. The cervical dorsal root ganglia 2-4 on the left were dissected out and these were pooled in the 3 groups. Ganglia were fixed in 2% paraformaldehyde/0.2% glutaraldehyde in PBS on ice for 1 hour. They were then stained for  $\beta$ -galactosidase activity using the X-gal reagent.

Ganglia were whole mounted under cover-slips, and examined under the microscope. In the C3b<sup>+</sup> infected mice, 3 of the ganglia were very strongly positive with high level  $\beta$ -galactosidase expression, and it was impossible to count individual neurons. The day 5 L $\beta$ A infected ganglia showed some positive staining, but this was not nearly as strong as that seen with the virus containing the CMV IE promoter. There were on average 8.4 positive neurons per ganglion. By day 26 after L $\beta$ A infection, there was continuing  $\beta$ -galactosidase expression, and this was seen at a higher level, and in more neurons, 20.3 per ganglion on average. Hence, activity of the native LAP is greater

in latently infected than acutely infected neurons, as would be expected, and efficient expression from the IRES-reporter gene construct persists into latency.

At day 82 post-infection with L $\beta$ A virus high level  
5  $\beta$ -galactosidase expression was still seen in dorsal root ganglia at an average of 20.5 blue neurones per ganglion examined. Examination at this time of brainstem and spinal cord showed abundant  $\beta$ -galactosidase expression in large numbers of neurones.  
10 Furthermore in ganglia and CNS tissue  $\beta$ -gal expression was detected in unidentified non-neuronal cell types - this is a novel finding. Ganglia containing a large number of neurones expressing  $\beta$ -galactosidase were readily detected 190 days post infection.

15 Data are shown in Figure 6a and Table 1. No obvious decrease in the average number of  $\beta$ -galactosidase expressing cells was evident throughout the time course of the experiments.

Following enumeration of  $\beta$ -gal positive neurones  
20 in whole mounted ganglia sampled at 82 and 190 days post infection, tissues were paraffin embedded and sectioned on a microtome. This allowed an assessment of the number of blue neuronal profiles within ganglionic sections to be made. At 82 days after  
25 infection, 261 blue neuronal profiles were detected in a total of 271 ganglionic sections (an average of 0.96



"blue" neuronal profiles per ganglionic section). From these data the conclusion is that there was no obvious decrease in the numbers of neurones expressing  $\beta$ -galactosidase in ganglia removed from mice at between  
5 82 and 190 days post-infection.

$\beta$ -galactosidase expression in the peripheral nervous system of mice infected with L $\beta$ B has also been examined. Figure 6b shows the numbers of "blue" neurones from whole mounted ganglia removed from  
10 animals at various times after infection. As observed for L $\beta$ A, we were able to demonstrate long-term  $\beta$ -galactosidase expression within latently-infected sensory neurones up to 140 days after infection. However, through the course of this experiment it was  
15 noted that the numbers of  $\beta$ -galactosidase positive cells per ganglion (Table 1), and the intensity of staining of cells, appeared to be less with this virus than as observed with L $\beta$ A. Whole mounted ganglia, sampled from L $\beta$ B infected animals at 140 days after  
20 infection, were embedded in paraffin, and sections scored for "blue" neuronal profiles. 59 positive neuronal profiles out of a total of 612 ganglionic sections were observed (an average of 0.1 "blue" neuronal profiles per ganglionic section) - a figure  
25 approximately 10-fold lower than that obtained from L $\beta$ A material sampled and analysed in a similar manner at 82

and 19. post infection. In order to determine whether the observed differences between L $\beta$ A and L $\beta$ B were due to differences in the efficiencies of lacZ during latency, *in situ* hybridisation (ISH) analyses were performed.

Cervical ganglia (CII-CIV) were dissected and pooled from mice latently infected with L $\beta$ A and L $\beta$ B at various time points, and processed for ISH. ISH was performed using a digoxigenin labelled riboprobe which was specific for the detection of lacZ mRNA. The data from these experiments are summarised in Table 1. At 82 days post-infection with L $\beta$ A, 44 lacZ RNA positive neuronal profiles were detected out of 167 ganglionic sections examined (an average of 0.26 lacZ positive neuronal profiles per ganglionic section), and at 1 days post infection, 42 lacZ RNA positive neuronal profiles were detected out of 162 ganglionic sections examined (an average of 0.26 lacZ positive neuronal profiles per ganglionic section). In each case the signal obtained was predominantly cytoplasmic, and the intensity of signal and mean number of lacZ positive neuronal profiles detected per section was similar at both time points. These data indicate the ability, continued transcription of lacZ specific RNA in sensory ganglia latently infected with L $\beta$ A.

ISH analyses using a LAT specific probe also resulted in the detection of transcripts within the cytoplasm of latently infected neurones, which is in sharp contrast to the characteristic nuclear localisation of LATs observed during latency with wild type viruses. The localisation of LATs and lacZ specific signals in the cytoplasm of neurones supports the view that hybrid transcripts are generated and transported to the cytoplasm of latently infected neurons. Interestingly, ISH detection of lacZ specific RNA in ganglia latently-infected with L $\beta$ B revealed a different pattern of signal than that observed with L $\beta$ A. Instead of the uniform cytoplasmic lacZ specific signal observed with L $\beta$ A, animals latently infected with L $\beta$ B demonstrated a predominantly nuclear, punctate signal, with a cytoplasmic signal observed in only some of the more intensely stained cells. At 140 days post infection with L $\beta$ B, ISH analyses revealed 23 lacZ positive neuronal positive profiles out of 128 ganglionic sections examined (an average of 0.18 neuronal lacZ positive profiles/ganglionic sections), and at 257 days post infection 102 lacZ positive profiles were observed in 288 ganglionic sections examined (an average of 0.36 lacZ positive neuronal profiles/ganglionic section). It therefore appears that L $\beta$ B established transcriptionally active latency

at an efficiency comparable to that of L $\beta$ A. However, despite the fact that similar numbers of latently infected neurones harbour transcriptionally active L $\beta$ A or L $\beta$ B genomes, fewer neurones latently infected with L $\beta$ B scored positive for functional  $\beta$ -galactosidase gene expression. The ISH data suggest that this may be a result of the relatively inefficient translocation of lacZ containing transcripts from the nucleus to the cytoplasm of neurones latently infected with L $\beta$ B rather than failure of LAT promoter mediated transcription.

*$\beta$ -galactosidase expression in neurones of the central nervous system from mice latently infected with L $\beta$ A*

Using the mouse ear model it has previously been demonstrated that, following the resolution of acute phase infection, animals harbour latent virus DNA in both brainstem and spinal cord tissue, as well as peripheral sensory ganglia (Efsthathiou et al. (1986) *J. Virol.* 57: 446-495). It is also well established that, using this model of infection, virus gains access to the brainstem via the facial nerve, which supplies motor fibres to the ear muscles (Hill et al. *Prog. Brain Res.* (1983) 59: 173-184).

We were, therefore, interested to determine whether latently infected animals would contain neurones expressing  $\beta$ -galactosidase at these sites. To

date our studies have focused on an examination of brainstems and cervical spinal cords of mice latently infected with recombinant virus L $\beta$ A, and has involved analysis of: 3 mice sampled at 2-3 months post infection; 2 mice sampled at 4 months post infection; 1 mouse sampled at 6 months post infection; and 11 mice sampled at 9-10 months post infection. As observed previously in our examination of  $\beta$ -galactosidase expression in latently infected sensory ganglia, there was considerable mouse to mouse variation in the level of transcriptionally active latency established. However, the anatomical distribution of  $\beta$ -galactosidase expression was maintained, and  $\beta$ -galactosidase expressing neurones were consistently detected in the cervical spinal cord, and bilaterally within the facial nerve nuclei and hypoglossal nerve nuclei.

$\beta$ -galactosidase expression was detected most frequently in the facial nerve nuclei (14 out of 17 mice examined), and 'blue' neurones were often observed throughout the nucleus (in up to 13 consecutive 60  $\mu$ m sections), with some neurones showing tracking of  $\beta$ -galactosidase into the dendritic tree and axon. The wide distribution of latently infected 'blue' neurones within the facial nucleus would be indicative of virus spread within the nucleus during acute infection.  $\beta$ -galactosidase positive neurones were detected in the

hypoglossal nuclei in 8 of the 17 animals examined. Latently infected 'blue' neurones were again commonly observed throughout the nucleus (in up to 15 consecutive 60  $\mu$ m sections). Cervical spinal cord was not obtained from all mice but  $\beta$ -galactosidase expression was observed in both anterior and posterior horn neurones in 6 out of 14 mice examined. We have observed occasional  $\beta$ -galactosidase expressing neurones in the region of the dorsal column sensory nuclei within the posterior caudal medulla of some mice as well as 'blue' axonal profiles traversing this area. These are likely to represent axons projecting from latently infected sensory neurones located in dorsal root ganglia.

15

The results obtained using embodiments of the present invention are in sharp contrast to most other attempts to obtain long-term gene expression from HSV based vectors, where gene expression has been at its strongest during the acute infection, and then tailed off during establishment of latency.

20

Examination of brainstem and spinal cord tissues of mice latently infected with LBA revealed  $\beta$ -galactosidase positive neurones in a number of distinct regions of the CNS at time points ranging from 72 to 307 days after infection.

25

For construction of a long-term expression cassette which can be used in other vector systems, the LAP-IRES  $\beta$ -geo cassette is being cloned into other regions of the virus, and into an amplicon vector.

5 This is by cloning the Not-I fragment which contains the LAP (from 118,439 to 122,025 bp) and/or a HpaI fragment (nucleotides 117,010 to 120,301) from the Bam HI B fragment of HSV-1 into the NotI site of pcDNA3 (Invitrogen) to generate pcDNA3/LAT. The XbaI fragment

10 of pCA-1 is then cloned downstream of the LAP sequence at a position corresponding to HSV nucleotide 120,301 in pcDNA3/LAT. The LAP-IRES  $\beta$ -geo cassette can now be excised as a NotI fragment and cloned into HSV amplicons or into other viral loci, or used as a

15 plasmid for naked DNA delivery.

#### REFERENCES

1. Spaete & Frenkel, *Cell* 30, 295-304 (1982).
2. During, et al., *Science* 266, 1399-403 (1994).
- 20 3. Feldman, *Seminars in virology* 5, 207-212 (1994).
4. Goins, et al., *J Virol* 68, 2239-52 (1994).
5. Deshmane, et al., *Virology* 196, 868-72 (1993).
6. Nicosia, et al., *J Virol* 67, 7276-83 (1993).
7. Block, et al., *Virology* 192, 618-30 (1993).
- 25 8. Dobson, et al., *J Virol* 63, 3844-51 (1989).
9. Margolis, et al., *Virology* 197, 585-92 (1993).

10. Gibson, et al., *Neuron* 5, 353-60 (1990).
11. Sgard, et al., *J Virol* 68, 7148-58 (1994).
12. W et al., *Nat Genet* 1, 379-84 (1992).
13. Miyanochara, et al., *New Biol* 4, 238-46 (1992).
- 5 14. Fink, et al., *Hum Gene There* 3, 11-9 (1992).
15. Weir et al., *PNAS USA* 90, 9140-4 (1993).
16. Andersen, et al., *Hum Gene There* 3, 487-99 (1992).
17. Palmer, et al., *Nucleic Acid Res* 21, 3451-7  
(1993).



Table 1

Virus	Days post infection	Average number of blue neurones per ganglion (range)	ISH positive neuronal profiles per ganglionic section
LBA	4	8.4 (0-55)	ND
	26	17.1 (0-53)	ND
	82	19.8 (0-55)	0.26 (44/167)
	190	14.7 (0-85)	0.26 (42/162)
LBB	5	2.8 (0-12)	ND
	32	11.7 (0-43)	0.36 (68/187)
	140	14.4 (1-32)	0.18 (23/128)
	257	ND	0.36 (102/288)

Detection of  $\beta$ -galactosidase expression by histochemical staining and by ISH for mRNA in the peripheral nervous system of mice infected with LBA and LBB.

CLAIMS

1. A nucleic acid construct including (i) a portion of the *latency associated transcript* (LAT) region of a herpes virus genome, which portion includes a *latency active promoter* (LAP), (ii) an internal ribosome entry site (IRES) downstream of the promoter, and (iii) a nucleotide sequence downstream of the IRES and heterologous to the LAT region.
2. A nucleic acid construct according to claim 1 wherein the heterologous nucleotide sequence encodes a polypeptide.
3. A nucleic acid construct according to claim 1 or claim 2 which is part of a vector.
4. A nucleic acid construct according to claim 3 wherein the vector is a viral vector.
5. A nucleic acid construct according to claim 4 wherein the vector is a herpes viral vector.
6. A nucleic acid construct according to claim 5 wherein the LAT region is native to the herpes virus of the vector.
7. A nucleic acid construct according to any of

claims 4 to 6 wherein the viral vector is replication defective.

8. A nucleic acid construct according to any  
5 preceding claim wherein the herpes virus is herpes simplex virus 1 (HSV1).

9. A nucleic acid construct according to any  
preceding claim wherein the IRES is a picornavirus  
10 IRES.

10. A cell containing a nucleic acid construct  
according to any preceding claim.

15 11. A cell according to claim 10 wherein the heterologous nucleotide sequence is being expressed.

12. A cell according to claim 10 or claim 11 which is  
a nerve cell.

20 13. A cell according to any of claims 10 to 12 which is part of a mammal.

14. A mammal having a cell according to any of claims  
25 10 to 12.

15. A mammal containing a nucleic acid construct

50

according to any of claims 1 to 9.

16. A method including introduction of a nucleic acid construct according to any of claims 1 to 9 into a  
5 cell.

17. A method according to claim 16 wherein the cell is a nerve cell.

10 18. A method according to claim 16 or claim 17 wherein said introduction takes place *ex vivo*.

19. A method which includes causing or allowing expression of a heterologous nucleotide sequence in a  
15 nucleic acid construct according to any of the claims 1 to 9 in a cell.

20. A method according to claim 19 wherein the cell is part of a mammal.

20

21. A herpes virus including in its genome an internal ribosome entry site (IRES) downstream of the herpes virus *latency active promoter* (LAP) and a non-herpes virus nucleotide sequence downstream of the IRES.

25

22. A herpes virus according to claim 21 which is replication defective or attenuated.

51

23. A cell containing a herpes virus according to claim 21 or claim 22.

24. A mammal having a cell according to claim 23.

5

25. A method which includes administering to a mammal a nucleic acid construct according to any of claims 1 to 9.


10

26. A method according to claim 25 wherein a virus containing the nucleic acid construct is administered to the mammal.

15


27. A method which includes administering to a mammal a cell according to any of claims 10 to 12.

28. A method which includes administering to a mammal a herpes virus according to claim 21 or claim 22.



pMENA	Mo	EMCV	neo	A(n)
pΔMENA	Mo	EMCV	neo	A(n)

Fig.2.



3/7




Fig.3.






Fig. 4.








Fig.5.




6/7

Fig.6a.



7/7

Fig.6b.





## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 15/38, 5/16, 7/00, A01K 67/027</b>	<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 97/20935</b> <b>(43) International Publication Date:</b> 12 June 1997 (12.06.97)
<b>(21) International Application Number:</b> PCT/GB96/03033 <b>(22) International Filing Date:</b> 6 December 1996 (06.12.96) <b>(30) Priority Data:</b> 9524973.6 6 December 1995 (06.12.95) GB <b>(71) Applicant (for all designated States except US):</b> CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED [GB/GB]; The Old Schools, Cambridge CB2 1TS (GB). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> EFSTATHIOU, Stacey [GB/GB]; 18 Norwich Street, Cambridge CB2 1NE (GB). LACHMANN, Robin, Henry [GB/GB]; 45 Rathmore Road, Cambridge CB1 4AB (GB). <b>(74) Agents:</b> WALTON, Seán, M. et al.; Mewburn Ellis, York House, 23 Kingsway, London WC2B 6HP (GB).	<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>  <b>(88) Date of publication of the international search report:</b> 28 August 1997 (28.08.97)	
<b>(54) Title:</b> VIRAL VECTORS  <b>(57) Abstract</b>  Constructs for delivery of sequences of interest to cells include a herpes virus <i>latency active promoter</i> (LAP) of the <i>latency associated transcript</i> (LAT) region. An internal ribosome entry site (IRES) is located downstream of the LAP, with a nucleotide sequence of interest downstream of the IRES. Stable, long-term expression, including export of mRNA to the cytoplasm and translation of the encoded polypeptide, is found in neuronal and non-neuronal cells.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

# INTERNATIONAL SEARCH REPORT

Int. l. Application No  
PCT/GB 96/03033

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 C12N15/38 C12N5/16 C12N7/00 A01K67/027

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 C12N A01K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	BRITISH MEDICAL BULLETIN, vol. 51, no. 1, 1995, pages 45-55, XP002033065 S. EFSTATHIOU AND A.C. MINSON: "Herpes virus-based vectors" *see the whole article*	1-28
Y	MOLECULAR BIOTECHNOLOGY, vol. 4, 1995, pages 87-99, XP000654354 J.C. GLORIOSO ET AL.: "HSV as a gene transfer vector for the nervous system" *SEE THE WHOLE ARTICLE*	1-28
	- / - -	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

16 June 1997

Date of mailing of the international search report

08.07.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+ 31-70) 340-3016

Authorized officer

Marie, A

# INTERNATIONAL SEARCH REPORT

Int. Application No  
PCT/GB 96/03033

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>NEW BIOL., vol. 4, no. 3, 1992, pages 238-246, XP000650666 A. MIYANOHARA ET AL.: "Direct gene transfer to the liver with HSV-1 vectors: transient production of physiologically relevant levels of circulating factor IX" *see the whole article*</p> <p style="text-align: center;">---</p>	1-28
Y	<p>WO 94 24301 A (THE UNIVERSITY OF EDINBURGH) 27 October 1994 *see the whole patent*</p> <p style="text-align: center;">---</p>	1-28
Y	<p>WO 93 03143 A (W. ANDERSON ET AL.) 18 February 1993 *see the whole patent*</p> <p style="text-align: center;">-----</p>	1-28



# INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. Appl. No.  
PCT/GB 96/03033

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9424301 A	27-10-94	AU 678233 B	22-05-97
		AU 6542694 A	08-11-94
		AU 678234 B	22-05-97
		AU 6542794 A	08-11-94
		CA 2161089 A	27-10-94
		EP 0695351 A	07-02-96
		EP 0695361 A	07-02-96
		WO 9424274 A	27-10-94
		JP 9500004 T	07-01-97
		JP 9500005 T	07-01-97
		NZ 265090 A	24-03-97
		ZA 9402719 A	09-01-95
		ZA 9402720 A	30-03-95
WO 9303143 A	18-02-93	CA 2114416 A	18-02-93
		EP 0598029 A	25-05-94
		JP 6509713 T	02-11-94